Desmarais LLP earned nominations in five categories for the Managing IP Americas Awards 2025, which recognizes the firm’s recent string of victories in the district and appellate courts and before the International Trade Commission and Patent Trial and Appeal Board.
These wins include a noninfringement defense verdict that eliminated $361 million in damages related to encryption security patents; a $44.9 million jury verdict that found two interactive services patents were infringed; three separate Federal Circuit rulings that preserved $429.5 million in patent damages won in the district courts related to infringement of non-invasive prenatal genetic testing technology; and a defense victory that found no violation in a trade secret case before the ITC related to a strain of botulinum toxin used in Botox products.
The annual Managing IP Americas Awards program, now in its 20th year, highlights the industry’s leading law firms in their various practice areas and across more than 50 jurisdictions. Researchers assess thousands of intellectual property-focused firms and practitioners. Managing IP then compiles the shortlists based on information provided by the firms, client feedback, and reviews of public case records.
Desmarais LLP’s nominations include:
Desmarais LLP Defeats Labcorp’s Attempt to Undermine Ravgen’s Trial Victory
Accolades
Desmarais LLP earned a district court victory that rejected Labcorp’s attempt to retry a prior Ravgen victory. That jury trial victory resulted in a non-invasive prenatal genetic testing patent being found...
MORE
